Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 13/20 | 0.82 |
| ▸ | NPY4R | P50391 | 8/20 | 0.82 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.82 |
| ▸ | NPY1R | P25929 | 6/20 | 0.82 |
| ▸ | TFPI | P10646 | 5/20 | 0.69 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.64 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.64 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.63 |
| ▸ | CALCR | P30988 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30121639 | 0.94 | NPY2R (0.92) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| Neuropeptide-Y SCHEMBL31042464 | 0.94 | NPY2R (0.73) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| Human Neuropeptide Y SCHEMBL29523253 | 0.92 | NPY2R (0.70) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29351932 | 0.89 | CRHR1 (0.74) | NPY2RNPY4RNPY5RNPY1RCRHR1 | |
| Neuropeptide-Y SCHEMBL3051623 | 0.88 | NPY2R (0.82) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL31362091 | 0.88 | CRHR1 (0.69) | NPY2RNPY4RNPY5RNPY1RCRHR1 | |
| SCHEMBL29399759 | 0.88 | NPY2R (0.89) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL13248707 | 0.87 | NPY2R (0.80) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| Human Neuropeptide Y SCHEMBL29780330 | 0.86 | NPY2R (0.79) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29440046 | 0.86 | CRHR1 (0.77) | NPY2RNPY4RNPY5RNPY1RCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3307768-B1 | SELECTIVE PYY COMPOUNDS AND USES THEREOF | NOVO NORDISK AS (DK) | 2025-01-29 | — | — | EP | claimed |
| US-20230340039-A1 | NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2023-10-26 | — | — | US | claimed |
| EP-4009957-B1 | SOLID COMPOSITION COMPRISING A PYY COMPOUND AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | NOVO NORDISK AS (DK) | 2023-10-11 | — | — | EP | claimed |
| EP-4192853-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2023-06-14 | — | — | EP | claimed |
| CN-116171282-A | Soluble NPY2 receptor agonists | 勃林格殷格翰国际有限公司 | 2023-05-26 | — | — | CN | claimed |
| EP-4058047-A1 | NPY2 RECEPTOR AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2022-09-21 | — | — | EP | claimed |
| US-20220280611-A1 | SOLID COMPOSITION COMPRISING A PYY COMPOUND AND A SALT OF N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | NOVO NORDISK A/S (DK) | 2022-09-08 | — | — | US | claimed |
| CN-114641303-A | NPY2 receptor agonists | 勃林格殷格翰国际有限公司 | 2022-06-17 | — | — | CN | claimed |
| EP-4009957-A1 | SOLID COMPOSITION COMPRISING A PYY COMPOUND AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | Novo Nordisk A/S (DK) | 2022-06-15 | — | — | EP | claimed |
| CN-114206375-A | Solid compositions comprising a PYY compound and a salt of N- (8- (2-hydroxybenzoyl) amino) octanoic acid | 诺和诺德股份有限公司 | 2022-03-18 | — | — | CN | claimed |
| WO-2022029231-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-10 | — | — | WO | claimed |
| US-12559529-B2 | NPY2 receptor agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-02-24 | — | — | US | disclosed |
| US-20260015399-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2026-01-15 | — | — | US | disclosed |
| US-12391737-B2 | Soluble NPY2 receptor agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-19 | — | — | US | disclosed |
| US-20250223580-A1 | PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS | THE BROAD INSTITUTE, INC. | 2025-07-10 | — | — | US | disclosed |
| EP-3988123-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | Janssen Pharmaceutica NV (BE) | 2022-04-27 | — | — | EP | disclosed |
| US-11304992-B2 | Inhalable dry powder pharmaceutical composition | MANNKIND CORPORATION (US) | 2022-04-19 | — | — | US | disclosed |
| CN-114206375-A | Solid compositions comprising a PYY compound and a salt of N- (8- (2-hydroxybenzoyl) amino) octanoic acid | 诺和诺德股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220041678-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-10 | — | — | US | disclosed |
| WO-2022029231-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304992-B2 | Inhalable dry powder pharmaceutical composition | GLP1R, IAPP, SLC5A2 | NPY2R 12/4885NPY4R 40/4885NPY5R 42/4885 |
| US-20220280611-A1 | SOLID COMPOSITION COMPRISING A PYY COMPOUND AND A SALT OF N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | S100A8, SLC38A7, CAPRIN1 | NPY2R 24/4885NPY4R 69/4885NPY5R 27/4885 |
| US-20220041678-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | NPY2R, NPY1R, NPY5R | NPY2R 1/4885NPY4R 4/4885NPY5R 3/4885 |
| US-20230340039-A1 | NPY2 RECEPTOR AGONISTS | NPY2R, NPY1R, NPY5R | NPY2R 1/4885NPY4R 4/4885NPY5R 3/4885 |
| US-12391737-B2 | Soluble NPY2 receptor agonists | NPY2R, NPY1R, NPY5R | NPY2R 1/4885NPY4R 4/4885NPY5R 3/4885 |
| US-20260015399-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | NPY1R, NPY2R, NPY5R | NPY2R 2/4885NPY4R 4/4885NPY5R 3/4885 |
| US-12559529-B2 | NPY2 receptor agonists | NPY2R, NPY5R, NPY1R | NPY2R 1/4885NPY4R 4/4885NPY5R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.